A Study to Evaluate Erlotinib in Patients With Advanced or Metastatic Breast Cancer During or Following Chemotherapy

A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer

NCT02561832 ·Status: TERMINATED ·Phase: PHASE1

Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer

NCT05522491 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.

NCT03286842 ·Status: COMPLETED ·Phase: PHASE3

Study of Erlotinib and Metformin in Triple Negative Breast Cancer

NCT01650506 ·Status: COMPLETED ·Phase: PHASE1

An Open-Label, Expanded Access Protocol of Iniparib Breast Cancer

NCT01130259 ·Status: NO_LONGER_AVAILABLE

Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.

NCT00051103 ·Status: COMPLETED ·Phase: PHASE2

A Study of Patients With HER2 Gene Amplified Metastatic Breast Cancer Treated With First Line Herceptin and a Taxane

NCT00097487 ·Status: COMPLETED

Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients

NCT02681562 ·Status: UNKNOWN ·Phase: PHASE2

Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer

NCT03544125 ·Status: COMPLETED ·Phase: PHASE1

MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer

NCT01097460 ·Status: COMPLETED ·Phase: PHASE1

Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

NCT02000622 ·Status: COMPLETED ·Phase: PHASE3

Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer

NCT00031278 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Oral Vinorelbine and Capecitabine in Advanced HER2-negative Breast Cancer

NCT05747326 ·Status: UNKNOWN ·Phase: PHASE2

Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer

NCT07019337 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer

NCT05823623 ·Status: RECRUITING ·Phase: PHASE2

CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer

NCT00043394 ·Status: COMPLETED ·Phase: PHASE2

Olaparib In Metastatic Breast Cancer

NCT03344965 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Amonafide in Treating Women With Metastatic Breast Cancer That Has Progressed After Previous Chemotherapy

NCT00074100 ·Status: COMPLETED ·Phase: PHASE2

Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer

NCT03742245 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

A Study of Biweekly Gemcitabine, Paclitaxel, and Avastin in Patients With Metastatic Breast Cancer

NCT00618826 ·Status: COMPLETED ·Phase: PHASE2

Irinotecan in Treating Patients With Refractory Metastatic Breast Cancer

NCT00003351 ·Status: COMPLETED ·Phase: PHASE2

CP-724,714 in Treating Patients With Metastatic Breast Cancer

NCT00055926 ·Status: COMPLETED ·Phase: PHASE1

A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients

NCT04556292 ·Status: UNKNOWN ·Phase: PHASE2

PARP-inhibitor on Advanced Metastatic Breast Cancer in Germline PALB2 Mutations Carriers

NCT05232006 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Lapatinib in Combination With Oral Vinorelbine for Metastatic Breast Cancer

NCT00912275 ·Status: COMPLETED ·Phase: PHASE1/PHASE2